{"id":"imatinib-glivec","safety":{"commonSideEffects":[{"rate":"50-60","effect":"Nausea"},{"rate":"30-40","effect":"Vomiting"},{"rate":"40-50","effect":"Diarrhea"},{"rate":"25-35","effect":"Muscle cramps"},{"rate":"20-30","effect":"Edema"},{"rate":"15-25","effect":"Rash"},{"rate":"20-30","effect":"Fatigue"},{"rate":"10-30","effect":"Myelosuppression (anemia, neutropenia, thrombocytopenia)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Imatinib selectively inhibits the constitutively active BCR-ABL tyrosine kinase that results from the Philadelphia chromosome translocation in chronic myeloid leukemia (CML). By blocking this kinase, it prevents the downstream signaling that drives uncontrolled myeloid cell proliferation. The drug also inhibits KIT and PDGFRA kinases, making it effective in gastrointestinal stromal tumors (GISTs) driven by these mutations.","oneSentence":"Imatinib is a tyrosine kinase inhibitor that blocks the BCR-ABL fusion protein and other kinases, preventing abnormal cell proliferation in chronic myeloid leukemia and gastrointestinal stromal tumors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:18.029Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia (CML), Philadelphia chromosome positive"},{"name":"Gastrointestinal stromal tumor (GIST), KIT-positive"},{"name":"Acute lymphoblastic leukemia (ALL), Philadelphia chromosome positive"}]},"trialDetails":[{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT07493408","phase":"PHASE2","title":"Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-30","conditions":"Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia, Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)","enrollment":45},{"nctId":"NCT04394416","phase":"PHASE3","title":"Trial of Imatinib for Hospitalized Adults With COVID-19","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2020-06-02","conditions":"COVID-19","enrollment":21},{"nctId":"NCT07171203","phase":"PHASE1","title":"Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-06","conditions":"Gastrointestinal Stromal Tumors","enrollment":18},{"nctId":"NCT05143840","phase":"PHASE2","title":"Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"RECRUITING","sponsor":"Augusta University","startDate":"2022-04-22","conditions":"Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid","enrollment":100},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT00070499","phase":"PHASE2","title":"Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-08-15","conditions":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","enrollment":406},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT00044304","phase":"PHASE2","title":"Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-09-26","conditions":"Eosinophilic Myeloid Neoplasm, Hypereosinophilic Syndrome","enrollment":70},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT00421317","phase":"PHASE2","title":"Imatinib in Adult Patients With Metastatic Ocular Melanoma","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2005-12","conditions":"Melanoma","enrollment":13},{"nctId":"NCT01046487","phase":"PHASE1","title":"Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2009-02-09","conditions":"Cancer","enrollment":26},{"nctId":"NCT04971226","phase":"PHASE3","title":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-06","conditions":"Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive","enrollment":406},{"nctId":"NCT01746836","phase":"PHASE2","title":"Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-01-17","conditions":"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":50},{"nctId":"NCT04877522","phase":"PHASE4","title":"Asciminib Roll-over Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-08-30","conditions":"Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive","enrollment":347},{"nctId":"NCT05306301","phase":"PHASE2","title":"Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2022-10-05","conditions":"Chemotherapy, Leukemia, Acute Lymphoblastic","enrollment":32},{"nctId":"NCT03516279","phase":"PHASE2","title":"Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-06-26","conditions":"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease","enrollment":40},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT07413263","phase":"","title":"Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-05-01","conditions":"Chronic Myeloid Leukemia","enrollment":75},{"nctId":"NCT06090669","phase":"PHASE1","title":"Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-19","conditions":"Inherited Bone Marrow Failure Syndrome, Familial Platelet Disorder With Predisposition to Myeloid Malignancies","enrollment":75},{"nctId":"NCT05493215","phase":"PHASE2","title":"Imatinib TDM in GIST","status":"RECRUITING","sponsor":"Reema A. Patel","startDate":"2024-03-26","conditions":"Gastrointestinal Stromal Tumors","enrollment":28},{"nctId":"NCT07406633","phase":"PHASE2","title":"KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting","status":"NOT_YET_RECRUITING","sponsor":"Kumquat Biosciences Inc.","startDate":"2026-04","conditions":"GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer","enrollment":46},{"nctId":"NCT05381753","phase":"","title":"Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World","status":"COMPLETED","sponsor":"CStone Pharmaceuticals","startDate":"2022-08-29","conditions":"Gastrointestinal Stromal Tumors","enrollment":61},{"nctId":"NCT06655246","phase":"PHASE1","title":"A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2025-03-27","conditions":"Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm","enrollment":157},{"nctId":"NCT03673501","phase":"PHASE3","title":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2019-02-08","conditions":"Gastrointestinal Stromal Tumors","enrollment":453},{"nctId":"NCT01742299","phase":"PHASE4","title":"Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-26","conditions":"GIST and CML","enrollment":155},{"nctId":"NCT07218926","phase":"PHASE3","title":"A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-12-03","conditions":"Gastrointestinal Neoplasms","enrollment":450},{"nctId":"NCT03997903","phase":"PHASE1, PHASE2","title":"Imatinib for Pain in Sickle Cell Anemia","status":"TERMINATED","sponsor":"Indiana University","startDate":"2020-02-26","conditions":"Sickle Cell Disease","enrollment":7},{"nctId":"NCT03610971","phase":"PHASE2","title":"Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-11-19","conditions":"Chronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase","enrollment":24},{"nctId":"NCT06889168","phase":"PHASE1","title":"Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)","status":"RECRUITING","sponsor":"Columbia University","startDate":"2025-10-20","conditions":"Lymphangioleiomyomatosis (LAM), Lymphangioleiomyomatosis","enrollment":20},{"nctId":"NCT05245968","phase":"PHASE1","title":"A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2021-12-01","conditions":"Gastrointestinal Stromal Tumors","enrollment":78},{"nctId":"NCT06087263","phase":"PHASE2","title":"Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-06-18","conditions":"Gastrointestinal Stromal Tumors","enrollment":3},{"nctId":"NCT05152472","phase":"PHASE2","title":"A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2022-01-14","conditions":"Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor","enrollment":110},{"nctId":"NCT02891395","phase":"PHASE2","title":"Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2012-12-24","conditions":"Graft Versus Host Disease","enrollment":65},{"nctId":"NCT04626024","phase":"PHASE2","title":"Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2020-12-22","conditions":"Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission","enrollment":100},{"nctId":"NCT03654768","phase":"PHASE2","title":"Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2018-10-24","conditions":"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":81},{"nctId":"NCT05734105","phase":"PHASE3","title":"A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2023-12-13","conditions":"GIST","enrollment":54},{"nctId":"NCT02881086","phase":"PHASE3","title":"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","status":"COMPLETED","sponsor":"Goethe University","startDate":"2016-08","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1023},{"nctId":"NCT06682169","phase":"PHASE3","title":"Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-11-20","conditions":"Graft-versus-host Disease","enrollment":182},{"nctId":"NCT01991379","phase":"PHASE1, PHASE2","title":"MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-11","conditions":"Gastrointestinal Stromal Tumor (GIST)","enrollment":75},{"nctId":"NCT03589326","phase":"PHASE3","title":"A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2018-10-04","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)","enrollment":245},{"nctId":"NCT01771458","phase":"PHASE2","title":"A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2012-10","conditions":"Reccurent/Metastatic Solid Tumor Disease","enrollment":742},{"nctId":"NCT04070443","phase":"PHASE2","title":"Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Leon Berard","startDate":"2019-11-13","conditions":"Philadelphia Chromosome Positive CML, BCR-ABL Positive Chronic Myelogenous Leukemia","enrollment":170},{"nctId":"NCT05489237","phase":"PHASE1","title":"First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors","status":"RECRUITING","sponsor":"IDRx Inc. - A GSK Company","startDate":"2022-08-03","conditions":"Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease","enrollment":278},{"nctId":"NCT03578367","phase":"PHASE2","title":"Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-22","conditions":"CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic","enrollment":104},{"nctId":"NCT05623774","phase":"PHASE1","title":"A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg","status":"COMPLETED","sponsor":"Inhibikase Therapeutics","startDate":"2022-12-16","conditions":"CML","enrollment":64},{"nctId":"NCT00816114","phase":"","title":"Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-06-08","conditions":"Chronic Myelogenous Leukemia","enrollment":3000},{"nctId":"NCT01316250","phase":"NA","title":"Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","startDate":"2010-08","conditions":"Chronic Myelogenous Leukemia","enrollment":13},{"nctId":"NCT07188428","phase":"","title":"Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-27","conditions":"Leukemia, Chronic Myeloid","enrollment":2298},{"nctId":"NCT07022743","phase":"PHASE2","title":"Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Obafemi Awolowo University","startDate":"2025-07-01","conditions":"Chronic Myeloid Leukemia (CML)","enrollment":75},{"nctId":"NCT07158294","phase":"NA","title":"Identification of BCR::ABL1 Mutations by Digital PCR in CML","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2026-02-01","conditions":"Chronic Myeloid Leukemia (CML)","enrollment":150},{"nctId":"NCT07151820","phase":"","title":"A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-08","conditions":"Leukemia, Chronic Myeloid","enrollment":2546},{"nctId":"NCT05816785","phase":"EARLY_PHASE1","title":"Pilot Study of Imatinib Cetuximab Combo for H & N Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-04-18","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck","enrollment":15},{"nctId":"NCT04598009","phase":"PHASE2","title":"Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-03-03","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":25},{"nctId":"NCT01698905","phase":"PHASE2","title":"Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-20","conditions":"Chronic Myeloid Leukemia","enrollment":163},{"nctId":"NCT00777036","phase":"PHASE2","title":"A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-03-20","conditions":"Leukemia","enrollment":133},{"nctId":"NCT01347216","phase":"","title":"COMPERA / COMPERA-KIDS","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2007-07-01","conditions":"Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)","enrollment":14000},{"nctId":"NCT01907607","phase":"PHASE2","title":"Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2014-02","conditions":"Advanced Gastrointestinal Stromal Tumors","enrollment":29},{"nctId":"NCT00015847","phase":"PHASE2","title":"Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2001-04","conditions":"Leukemia","enrollment":25},{"nctId":"NCT00265798","phase":"PHASE2","title":"Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-09-14","conditions":"Gastrointestinal Stromal Tumor","enrollment":38},{"nctId":"NCT03112603","phase":"PHASE3","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-06-29","conditions":"Graft-versus-host Disease (GVHD)","enrollment":330},{"nctId":"NCT05385549","phase":"PHASE2","title":"5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-09-07","conditions":"Gastrointestinal Stromal Tumors","enrollment":35},{"nctId":"NCT07096609","phase":"PHASE1, PHASE2","title":"Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-09-08","conditions":"GIST","enrollment":48},{"nctId":"NCT04838041","phase":"PHASE2","title":"Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-11-11","conditions":"Chronic Phase Chronic Myelogenous Leukemia","enrollment":51},{"nctId":"NCT07091019","phase":"","title":"A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-11-15","conditions":"Chronic Myelogenous Leukemia - Chronic Phase","enrollment":1000},{"nctId":"NCT05722795","phase":"NA","title":"Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2023-06-01","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":40},{"nctId":"NCT03469011","phase":"PHASE1","title":"A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2018-09-18","conditions":"Papillary Thyroid Cancer","enrollment":14},{"nctId":"NCT04129931","phase":"PHASE2","title":"PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2019-12-19","conditions":"Asthma","enrollment":395},{"nctId":"NCT00476190","phase":"PHASE2","title":"ALL Adult Consortium Trial: Adult ALL Trial","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-04","conditions":"Acute Lymphoblastic Leukemia","enrollment":112},{"nctId":"NCT01860456","phase":"","title":"TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2013-05","conditions":"Chronic Myeloid Leukemia","enrollment":412},{"nctId":"NCT01751425","phase":"PHASE1","title":"Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-07-24","conditions":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Minimal Residual Disease","enrollment":8},{"nctId":"NCT05413915","phase":"PHASE3","title":"Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarit Assouline","startDate":"2023-11-01","conditions":"Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, Chronic Myeloid Leukemia in Remission","enrollment":164},{"nctId":"NCT06962254","phase":"PHASE1","title":"Imatinib and Trametinib for KRAS-mutated Solid Tumor","status":"RECRUITING","sponsor":"China Medical University Hospital","startDate":"2025-05-10","conditions":"Solid Tumor Cancer","enrollment":10},{"nctId":"NCT05071482","phase":"PHASE4","title":"Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL","status":"TERMINATED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-09-16","conditions":"Acute Leukemia","enrollment":39},{"nctId":"NCT06061094","phase":"PHASE2","title":"Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT","status":"RECRUITING","sponsor":"Goethe University","startDate":"2023-07-14","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","enrollment":220},{"nctId":"NCT03632135","phase":"PHASE3","title":"Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Cordgenics, LLC","startDate":"2018-05-20","conditions":"Recurrent Glioblastoma","enrollment":78},{"nctId":"NCT06917196","phase":"","title":"PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2023-12-04","conditions":"Pulmonary Arterial Hypertension (PAH), Lung Fibrosis Interstitial","enrollment":16},{"nctId":"NCT01085617","phase":"","title":"Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University College, London","startDate":"2010-12","conditions":"Leukemia, Mucositis, Oral Complications","enrollment":""},{"nctId":"NCT03844360","phase":"PHASE4","title":"Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease","status":"RECRUITING","sponsor":"Wei Zhao","startDate":"2016-01-31","conditions":"Hematological Neoplasms","enrollment":1500},{"nctId":"NCT02852486","phase":"PHASE2","title":"Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2016-06-22","conditions":"Leukemia, Chronic Myeloid","enrollment":31},{"nctId":"NCT05282108","phase":"","title":"Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia","status":"RECRUITING","sponsor":"Hikma Pharmaceuticals LLC","startDate":"2022-07-20","conditions":"Chronic Myeloid Leukemia","enrollment":240},{"nctId":"NCT06119789","phase":"PHASE2","title":"Precision Cancer Therapy in Rare Cancers","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2025-03-20","conditions":"Rare Malignant Neoplasm","enrollment":96},{"nctId":"NCT01804985","phase":"PHASE2","title":"De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2013-12","conditions":"Chronic Myeloid Leukaemia","enrollment":174},{"nctId":"NCT02413736","phase":"PHASE3","title":"Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST","status":"ACTIVE_NOT_RECRUITING","sponsor":"Heikki Joensuu","startDate":"2015-05","conditions":"Sarcoma","enrollment":255},{"nctId":"NCT03906292","phase":"PHASE2","title":"Frontline Asciminib Combination in Chronic Phase CML","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Jena","startDate":"2019-08-19","conditions":"Chronic Myeloid Leukemia","enrollment":125},{"nctId":"NCT04126681","phase":"PHASE2","title":"A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"COMPLETED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2019-10-21","conditions":"Chronic Myeloid Leukemia, Chronic Phase","enrollment":144},{"nctId":"NCT06038552","phase":"","title":"Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2002-01-01","conditions":"GIST, Malignant, Liver Metastases","enrollment":238},{"nctId":"NCT02401815","phase":"PHASE1, PHASE2","title":"CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Cogent Biosciences, Inc.","startDate":"2015-03-06","conditions":"Gastrointestinal Stromal Tumors","enrollment":51},{"nctId":"NCT04423185","phase":"PHASE2","title":"PLATFORM Study of Precision Medicine for Rare Tumors","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-08-15","conditions":"Rare Tumor","enrollment":770},{"nctId":"NCT04633122","phase":"PHASE2","title":"A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib","status":"COMPLETED","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2020-11-25","conditions":"Gastrointestinal Stromal Tumor(GIST)","enrollment":108},{"nctId":"NCT04722848","phase":"PHASE3","title":"Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2021-09-08","conditions":"Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL","enrollment":236},{"nctId":"NCT02398825","phase":"PHASE2","title":"Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib","status":"TERMINATED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2016-06-23","conditions":"Chronic Myeloid Leukemia, Chronic Phase, Adults","enrollment":14},{"nctId":"NCT05682924","phase":"","title":"Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib","status":"RECRUITING","sponsor":"Samara State Medical University","startDate":"2022-10-01","conditions":"Chronic Myeloid Leukaemia","enrollment":105},{"nctId":"NCT06219733","phase":"PHASE2","title":"Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)","status":"WITHDRAWN","sponsor":"MedPacto, Inc.","startDate":"2021-06-01","conditions":"Dermoid","enrollment":""},{"nctId":"NCT04147533","phase":"PHASE2","title":"Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masaryk University","startDate":"2020-06-16","conditions":"Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug","enrollment":150},{"nctId":"NCT06692803","phase":"","title":"Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-23","conditions":"Chronic Myeloid Leukemia","enrollment":2043},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT06051409","phase":"PHASE3","title":"A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2023-08-31","conditions":"Ph+ ALL","enrollment":350},{"nctId":"NCT03722420","phase":"PHASE3","title":"Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2018-12-28","conditions":"Chronic Myeloid Leukemia, Chronic Phase","enrollment":238}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Glivec","Gleevec"],"phase":"phase_3","status":"active","brandName":"Imatinib (Glivec)","genericName":"Imatinib (Glivec)","companyName":"Dermatologic Cooperative Oncology Group","companyId":"dermatologic-cooperative-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Imatinib is a tyrosine kinase inhibitor that blocks the BCR-ABL fusion protein and other kinases, preventing abnormal cell proliferation in chronic myeloid leukemia and gastrointestinal stromal tumors. Used for Chronic myeloid leukemia (CML), Philadelphia chromosome positive, Gastrointestinal stromal tumor (GIST), KIT-positive, Acute lymphoblastic leukemia (ALL), Philadelphia chromosome positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}